Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies

NCT05362773 is registered in ClinicalTrials.gov with MacroGenics as lead sponsor.

NCT NCT05362773
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT05362773 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Phase 1, First-in-Human, Dose Escalation Study of MGD024, a CD123 x CD3 Bispecific DART Molecule, in Patients With Select Relapsed or Refractory Hematologic Malignancies
Lead sponsor
MacroGenics
Phase
Phase 1
Overall status
Active, not recruiting
Start date
July 13, 2022
Completion date
May 31, 2027
Enrollment
130 (estimated)
Sites
7

Conditions

As the registry lists them; a condition with its own page is linked.

blastic plasmacytoid dendritic cell neoplasm, chronic myeloid leukemia, classical hodgkin lymphoma, leukemia, acute myeloid, leukemia, b-cell, leukemia, hairy cell, mastocytosis, aggressive systemic, myelodysplastic syndromes